Tags

Type your tag names separated by a space and hit enter

Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment.

Abstract

Subjects with mild cognitive impairment (MCI) are at a high risk of developing clinical Alzheimer's disease (AD). We asked to what extent the core biomarker candidates cerebro-spinal fluid (CSF) beta-amyloid(1-42) (Abeta(1-42)) and CSF tau protein concentrations predict conversion from MCI to AD. We studied 52 patients with MCI, 93 AD patients, and 10 healthy controls (HC). The MCI group was composed of 29 patients who had converted to AD during follow-up, and of 23 patients who showed no cognitive decline. CSF Abeta(1-42) and tau protein levels were assessed at baseline in all subjects, using enzyme-linked immunosorbent assays. For assessment of sensitivity and specificity, we used independently established reference values for CSF Abeta(1-42) and CSF tau. The levels of CSF tau were increased, whereas levels of Abeta(1-42) were decreased in MCI subjects. Abeta(1-42) predicted AD in converted MCI with a sensitivity of 59% and a specificity of 100% compared to HC. Tau yielded a greater sensitivity of 83% and a specificity of 90%. In a multiple Cox regression analysis within the MCI group, low baseline levels of Abeta(1-42), but not other predictor variables (tau protein, gender, age, apolipoprotein E epsilon4 carrier status, Mini Mental Status Examination score, observation time, antidementia therapy), correlated with conversion status (P<0.05). Our findings support the notion that CSF tau and Abeta(1-42) may be useful biomarkers in the early identification of AD in MCI subjects.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Department of Psychiatry, Alzheimer Memorial Center and Geriatric Psychiatry Branch, Dementia Research Section and Memory Clinic, Ludwig-Maximilian University, Nussbaumstrasse 7, 80336 Munich, Germany.

    , , , , , , , , , , ,

    Source

    Molecular psychiatry 9:7 2004 Jul pg 705-10

    MeSH

    Aged
    Aged, 80 and over
    Alzheimer Disease
    Amyloid beta-Peptides
    Apolipoprotein E4
    Apolipoproteins E
    Biomarkers
    Cognition Disorders
    Female
    Humans
    Male
    Middle Aged
    Peptide Fragments
    Predictive Value of Tests
    Prognosis
    Proportional Hazards Models
    Sensitivity and Specificity
    Severity of Illness Index
    tau Proteins

    Pub Type(s)

    Journal Article
    Research Support, Non-U.S. Gov't

    Language

    eng

    PubMed ID

    14699432

    Citation

    Hampel, H, et al. "Value of CSF Beta-amyloid1-42 and Tau as Predictors of Alzheimer's Disease in Patients With Mild Cognitive Impairment." Molecular Psychiatry, vol. 9, no. 7, 2004, pp. 705-10.
    Hampel H, Teipel SJ, Fuchsberger T, et al. Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. Mol Psychiatry. 2004;9(7):705-10.
    Hampel, H., Teipel, S. J., Fuchsberger, T., Andreasen, N., Wiltfang, J., Otto, M., ... Buerger, K. (2004). Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. Molecular Psychiatry, 9(7), pp. 705-10.
    Hampel H, et al. Value of CSF Beta-amyloid1-42 and Tau as Predictors of Alzheimer's Disease in Patients With Mild Cognitive Impairment. Mol Psychiatry. 2004;9(7):705-10. PubMed PMID: 14699432.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. AU - Hampel,H, AU - Teipel,S J, AU - Fuchsberger,T, AU - Andreasen,N, AU - Wiltfang,J, AU - Otto,M, AU - Shen,Y, AU - Dodel,R, AU - Du,Y, AU - Farlow,M, AU - Möller,H-J, AU - Blennow,K, AU - Buerger,K, PY - 2003/12/31/pubmed PY - 2005/1/5/medline PY - 2003/12/31/entrez SP - 705 EP - 10 JF - Molecular psychiatry JO - Mol. Psychiatry VL - 9 IS - 7 N2 - Subjects with mild cognitive impairment (MCI) are at a high risk of developing clinical Alzheimer's disease (AD). We asked to what extent the core biomarker candidates cerebro-spinal fluid (CSF) beta-amyloid(1-42) (Abeta(1-42)) and CSF tau protein concentrations predict conversion from MCI to AD. We studied 52 patients with MCI, 93 AD patients, and 10 healthy controls (HC). The MCI group was composed of 29 patients who had converted to AD during follow-up, and of 23 patients who showed no cognitive decline. CSF Abeta(1-42) and tau protein levels were assessed at baseline in all subjects, using enzyme-linked immunosorbent assays. For assessment of sensitivity and specificity, we used independently established reference values for CSF Abeta(1-42) and CSF tau. The levels of CSF tau were increased, whereas levels of Abeta(1-42) were decreased in MCI subjects. Abeta(1-42) predicted AD in converted MCI with a sensitivity of 59% and a specificity of 100% compared to HC. Tau yielded a greater sensitivity of 83% and a specificity of 90%. In a multiple Cox regression analysis within the MCI group, low baseline levels of Abeta(1-42), but not other predictor variables (tau protein, gender, age, apolipoprotein E epsilon4 carrier status, Mini Mental Status Examination score, observation time, antidementia therapy), correlated with conversion status (P<0.05). Our findings support the notion that CSF tau and Abeta(1-42) may be useful biomarkers in the early identification of AD in MCI subjects. SN - 1359-4184 UR - https://www.unboundmedicine.com/medline/citation/14699432/Value_of_CSF_beta_amyloid1_42_and_tau_as_predictors_of_Alzheimer's_disease_in_patients_with_mild_cognitive_impairment_ L2 - http://dx.doi.org/10.1038/sj.mp.4001473 DB - PRIME DP - Unbound Medicine ER -